GlassScriptPhysician profile
Sharyl E Balkin
NPI 1740396134
$9,646.00
in general payments reported to CMS, 2019-2025
31 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $1,032 · 2021: $1,224 · 2022: $1,164 · 2023: $1,413 · 2024: $1,861 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,745.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,389.17 | 2021-2025 | Vraylar |
| Lundbeck LLC | $855.30 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $837.62 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $805.38 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $715.69 | 2019-2025 | Rexulti |
| Corium, LLC | $468.79 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $409.30 | 2019-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $397.54 | 2021-2025 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $363.87 | 2019-2025 | Adzenys Xr-Odt |
| Almatica Pharma LLC | $350.55 | 2021-2025 | Loreev Xr |
| Allergan, INC. | $349.56 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.71 | 2020-2025 | Caplyta |
| Tris Pharma INC | $248.74 | 2022-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $231.39 | 2019-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $225.23 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $224.30 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $156.63 | 2022-2025 | Ingrezza |
| Vertical Pharmaceuticals, LLC | $152.17 | 2019-2025 | Relexxii |
| Supernus Pharmaceuticals, INC. | $150.69 | 2021-2024 | Qelbree, Qelbree |
| Adlon Therapeutics L.P. | $149.07 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $131.29 | 2019-2022 | |
| Inari Medical, INC. | $126.45 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novo Nordisk INC | $121.76 | 2024 | |
| Shire North American Group INC | $120.11 | 2019 | |
| Idorsia Pharmaceuticals US INC | $109.58 | 2022-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $66.07 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $61.72 | 2020 | |
| Owp Pharmaceuticals, INC. | $34.62 | 2019 | |
| Noven Therapeutics, LLC | $33.23 | 2024 | Secuado, Xelstrym |
| Eisai INC. | $32.04 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharyl Balkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.